Alessia Melani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alessia Melani has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Felicita Pedata
Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy
4 shared publications - Francesca Corti
University of Florence
3 shared publications Felicita Pedata
Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy
2 shared publications- Lucrezia Cellai
University of Florence
2 shared publications Anna Maria Pugliese
Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Division of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy
1 shared publication- Chiara Donati
Department of Experimental and Clinical Biomedical Sciences M. Serio, University of Florence, Florence, Italy
1 shared publication
Latest Publications
- 1 October 2017
- Published by Elsevier in Experimental Gerontology
- Vol. 96, 46-62
The neuron-astrocyte-microglia triad in CA3 after chronic cerebral hypoperfusion in the rat: Protective effect of dipyridamole
- 1 October 2017
- Published by Elsevier in Experimental Gerontology
- Vol. 96, 46-62
The neuron-astrocyte-microglia triad in CA3 after chronic cerebral hypoperfusion in the rat: Protective effect of dipyridamole
- 25 March 2015
- Published by Springer Nature in Neurological Sciences
- Vol. 36 (8) , 1441-1448
Time-course of protection by the selective A2A receptor antagonist SCH58261 after transient focal cerebral ischemia
Evidence indicates that the adenosine A2A receptor subtype is of critical importance in stroke. In previous studies, in the model of permanent middle cerebral artery occlusion (pMCAo), the adenosine A2A receptor antagonist, SCH58261, administered soon after ischemia, proved protective against excessive glutamate outflow in the first 4 h after ischemia and against neurological deficit and tissue damage evaluated 24 h after pMCAo. In the present work, we investigated if neuroprotective effect of SCH58261 was maintained 7 days after transient MCAo (tMCAo). SCH58261 (0.01 mg/kg, i.p.), administered twice/day for 7 days, protected from neurological deficit 1 day after tMCAo, but no more after 5 and 7 days. Two days after tMCAo, SCH58261 did not reduce blood cell infiltration, evaluated as HIS-48 positive cells, into ischemic striatal and cortical tissue. Moreover, 7 days after tMCAo, SCH58261 has not protected ischemic areas from damage and has not ameliorated myelin organization into the ischemic striatum. Protection by the A2A receptor antagonist 24 h after ischemia is attributable to reduced excitotoxicity. Seven days after ischemia the early protective effect of the A2A receptor antagonist likely has been overwhelmed by a secondary damage due to blood cell infiltration and neuroinflammation.
- 25 March 2015
- Published by Springer Nature in Neurological Sciences
- Vol. 36 (8) , 1441-1448
Time-course of protection by the selective A2A receptor antagonist SCH58261 after transient focal cerebral ischemia
Evidence indicates that the adenosine A2A receptor subtype is of critical importance in stroke. In previous studies, in the model of permanent middle cerebral artery occlusion (pMCAo), the adenosine A2A receptor antagonist, SCH58261, administered soon after ischemia, proved protective against excessive glutamate outflow in the first 4 h after ischemia and against neurological deficit and tissue damage evaluated 24 h after pMCAo. In the present work, we investigated if neuroprotective effect of SCH58261 was maintained 7 days after transient MCAo (tMCAo). SCH58261 (0.01 mg/kg, i.p.), administered twice/day for 7 days, protected from neurological deficit 1 day after tMCAo, but no more after 5 and 7 days. Two days after tMCAo, SCH58261 did not reduce blood cell infiltration, evaluated as HIS-48 positive cells, into ischemic striatal and cortical tissue. Moreover, 7 days after tMCAo, SCH58261 has not protected ischemic areas from damage and has not ameliorated myelin organization into the ischemic striatum. Protection by the A2A receptor antagonist 24 h after ischemia is attributable to reduced excitotoxicity. Seven days after ischemia the early protective effect of the A2A receptor antagonist likely has been overwhelmed by a secondary damage due to blood cell infiltration and neuroinflammation.
- 1 March 2014
- Published by Elsevier in Brain Research
- Vol. 1551, 59-72
Low doses of the selective adenosine A2A receptor agonist CGS21680 are protective in a rat model of transient cerebral ischemia
- 1 March 2014
- Published by Elsevier in Brain Research
- Vol. 1551, 59-72
Low doses of the selective adenosine A2A receptor agonist CGS21680 are protective in a rat model of transient cerebral ischemia
- 1 January 2012
- Published by Elsevier in Experimental Neurology
- Vol. 233 (1) , 193-204
Ecto-ATPase inhibition: ATP and adenosine release under physiological and ischemic in vivo conditions in the rat striatum
- 1 January 2012
- Published by Elsevier in Experimental Neurology
- Vol. 233 (1) , 193-204
Ecto-ATPase inhibition: ATP and adenosine release under physiological and ischemic in vivo conditions in the rat striatum
- Open Access
- 12 April 2011
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 8 (1) , 1-14
Selective adenosine A2Areceptor agonists and antagonists protect against spinal cord injury through peripheral and central effects
Background: Permanent functional deficits following spinal cord injury (SCI) arise both from mechanical injury and from secondary tissue reactions involving inflammation. Enhanced release of adenosine and glutamate soon after SCI represents a component in the sequelae that may be responsible for resulting functional deficits. The role of adenosine A2Areceptor in central ischemia/trauma is still to be elucidated. In our previous studies we have demonstrated that the adenosine A2Areceptor-selective agonist CGS21680, systemically administered after SCI, protects from tissue damage, locomotor dysfunction and different inflammatory readouts. In this work we studied the effect of the adenosine A2Areceptor antagonist SCH58261, systemically administered after SCI, on the same parameters. We investigated the hypothesis that the main action mechanism of agonists and antagonists is at peripheral or central sites.Methods: Spinal trauma was induced by extradural compression of SC exposed via a four-level T5-T8 laminectomy in mouse. Three drug-dosing protocols were utilized: a short-term systemic administration by intraperitoneal injection, a chronic administration via osmotic minipump, and direct injection into the spinal cord.Results: SCH58261, systemically administered (0.01 mg/kg intraperitoneal. 1, 6 and 10 hours after SCI), reduced demyelination and levels of TNF-α, Fas-L, PAR, Bax expression and activation of JNK mitogen-activated protein kinase (MAPK) 24 hours after SCI. Chronic SCH58261 administration, by mini-osmotic pump delivery for 10 days, improved the neurological deficit up to 10 days after SCI. Adenosine A2Areceptors are physiologically expressed in the spinal cord by astrocytes, microglia and oligodendrocytes. Soon after SCI (24 hours), these receptors showed enhanced expression in neurons. Both the A2Aagonist and antagonist, administered intraperitoneally, reduced expression of the A2Areceptor, ruling out the possibility that the neuroprotective effects of the A2Aagonist are due to A2Areceptor desensitization. When the A2Aantagonist and agonist were centrally injected into injured SC, only SCH58261 appeared neuroprotective, while CGS21680 was ineffective.Conclusions: Our results indicate that the A2Aantagonist protects against SCI by acting on centrally located A2Areceptors. It is likely that blockade of A2Areceptors reduces excitotoxicity. In contrast, neuroprotection afforded by the A2Aagonist may be primarily due to peripheral effects.
- 12 April 2011
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 8 (1) , 1-14
Open AccessSelective adenosine A2Areceptor agonists and antagonists protect against spinal cord injury through peripheral and central effects
Background: Permanent functional deficits following spinal cord injury (SCI) arise both from mechanical injury and from secondary tissue reactions involving inflammation. Enhanced release of adenosine and glutamate soon after SCI represents a component in the sequelae that may be responsible for resulting functional deficits. The role of adenosine A2Areceptor in central ischemia/trauma is still to be elucidated. In our previous studies we have demonstrated that the adenosine A2Areceptor-selective agonist CGS21680, systemically administered after SCI, protects from tissue damage, locomotor dysfunction and different inflammatory readouts. In this work we studied the effect of the adenosine A2Areceptor antagonist SCH58261, systemically administered after SCI, on the same parameters. We investigated the hypothesis that the main action mechanism of agonists and antagonists is at peripheral or central sites.Methods: Spinal trauma was induced by extradural compression of SC exposed via a four-level T5-T8 laminectomy in mouse. Three drug-dosing protocols were utilized: a short-term systemic administration by intraperitoneal injection, a chronic administration via osmotic minipump, and direct injection into the spinal cord.Results: SCH58261, systemically administered (0.01 mg/kg intraperitoneal. 1, 6 and 10 hours after SCI), reduced demyelination and levels of TNF-α, Fas-L, PAR, Bax expression and activation of JNK mitogen-activated protein kinase (MAPK) 24 hours after SCI. Chronic SCH58261 administration, by mini-osmotic pump delivery for 10 days, improved the neurological deficit up to 10 days after SCI. Adenosine A2Areceptors are physiologically expressed in the spinal cord by astrocytes, microglia and oligodendrocytes. Soon after SCI (24 hours), these receptors showed enhanced expression in neurons. Both the A2Aagonist and antagonist, administered intraperitoneally, reduced expression of the A2Areceptor, ruling out the possibility that the neuroprotective effects of the A2Aagonist are due to A2Areceptor desensitization. When the A2Aantagonist and agonist were centrally injected into injured SC, only SCH58261 appeared neuroprotective, while CGS21680 was ineffective.Conclusions: Our results indicate that the A2Aantagonist protects against SCI by acting on centrally located A2Areceptors. It is likely that blockade of A2Areceptors reduces excitotoxicity. In contrast, neuroprotection afforded by the A2Aagonist may be primarily due to peripheral effects.